Chundong Yu, Ph.D. Professor. E-mail: cdyu@xmu.edu.cn

Education

1993, B.Sc., Zhongshan University;

1996, M.Sc., Xiamen University;

2002, Ph.D., University of Texas Health Science Center, Houston.

Professional Experience

2002-2006, Postdoctoral Fellow, Baylor College of Medicine;

2006-Present, Professor, School of Life Sciences, Xiamen University.

Research Area

Laboratory of Inflammation and Liver Diseases focuses on understanding the molecular basis of inflammation and liver diseases. The laboratory has two focuses: 1. To study the role of nuclear receptors and transcriptional coregulators in inflammation and inflammation-related diseases. 2. To study the role of nuclear receptors and transcriptional coregulators in liver metabolism and liver diseases such as liver injury, liver fibrosis and liver cancer.

Selected Publications

1.Hong Y^#, Chen Q^#, Wan Z, Zhang Y, Li B, Guo H, Huang C, Kong X, Mo P, Xiao N , Xu J, Ye Y^*, Yu C^*. Targeting nuclear receptor coactivator SRC-1 prevents colorectal cancer immune escape by reducing transcription and protein stability of PD-L1. Adv Sci (Weinh). 2024;11(33):e2310037.
2.Zhuang W^#, Liu C^#, HongY^#, Zheng Y, Huang M, Tang H, Zhao L, Huang Z, Tu M, Yu L, Chen J, Zhang Y, Chen X, Lin F, Gao Q, Yu C^*, Huang Y^*. Tumor-suppressive miR-4732-3p is sorted into fucosylated exosome by hnRNPK to avoid the inhibition of lung cancer progression. J Exp Clin Cancer Res. 2024;43(1):123.
3.Zhang Y^# , Li  B^#, Hong Y^#, Hong Z, Xia X, Mo P, Yu C^*, Chen W^*. Histone demethylase JMJD2D protects against enteric bacterial infection via up-regulating colonic IL-17F to induce β-defensin expression. PLoS Pathog. 2024;20(6):e1012316.
4.Li B^#, Zhang Y^#, Liu X, Zhang Z, Zhuang S, Zhong X, Chen W, Hong Y, Mo P, Lin S, Wang S, Yu C^*. Traditional Chinese medicine Pien-Tze-Huang ameliorates LPS-induced sepsis through bile acid-mediated activation of TGR5-STAT3-A20 signalling. J Pharm Anal. 2024;14(4):100915.
5.Kong  X^#, Liu Z^# , Zhang R^#, Xie F^#, Liang R , Zhang Y, Yu L, Yang W, Li X, Chen Q, Li B, Hong Y, Li M , Xia X, Gu L, Fu L, Li X, Shen Y^*, Wu T^*,  Yu C^*, Li W^*. JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication. JHEP Rep. 2023;5(10):100849.
6.Guo P^#, Chen Q^#, Peng K^#, Xie J, Liu J, Ren W, Tong Z, Li M, Xu J, Zhang Y^*, Yu C^*, Mo P^*. Nuclear receptor coactivator SRC-1 promotes colorectal cancer progression through enhancing GLI2-mediated Hedgehog signaling. Oncogene. 2022;41(20):2846-2859.
7.Chen Q, Zhuang S, Hong Y, Yang L, Guo P, Mo P, Peng K^*, Li W^*, Xiao N^*, Yu C^*. Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling. Oncogene. 2022;41(10):1421-1433.
8.Deng Y^#, Li M^#, Zhuo M, Guo P, Chen Q, Mo P, Li W^*, Yu C^*. Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression. J Biol Chem. 2021;296:100121.
9.Peng K^#, Zhuo M^#, Li M, Chen Q, Mo P^*, Yu C^*. Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression. Oncogene. 2020;39(47):7076-7091.
10.Li M^#, Deng Y^#, Zhuo M, Zhou H, Kong X, Xia X, Su Z, Chen Q, Guo P, Mo P, Yu C^*, Li W^*. Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote liver cancer initiation and progression. Theranostics. 2020;10(19):8863-8879.
11. Zhuo M^#, Chen W^#, Shang S, Guo P, Peng K, Li M, Mo P, Zhang Y, Qiu X^*, Li W^*, Yu C^*. Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling. Oncogene. 2020;39(16):3336-3353
12.Peng K, Kou L, Yu L, Bai C, Li M, Mo P, Li W^*, Yu C^*. Histone demethylase JMJD2D interacts with -catenin to induce transcription and activate colorectal cancer cell proliferation and tumor growth in mice. Gastroenterology. 2019;16:1112-1126.
13.Wan W^#, Peng K^#, Li M, Qin L, Tong Z, Yan J, Shen B, Yu C^*. Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1α. Oncogene. 2017;36: 3868–3877.
14.Mo P, Zhou Q, Guan L, Wang Y, Wang W, Miao M, Tong Z, Li M, Majaz S, Liu Y, Su G, Xu J, Yu C^*. Amplified in breast cancer 1 promotes colorectal cancer progression through enhancing notch signaling. Oncogene. 2015;34:3935-3945.
15.Liu Y, Tong Z, Li T, Chen Q, Zhuo L, Li W, Wu R-C, Yu C^*. Hepatitis B virus X protein stabilizes amplified in breast cancer 1 protein and cooperates with it to promote human hepatocellular carcinoma cell invasiveness. Hepatology. 2012;56(3):1015-1024.
16.Chen Q, Li W, Wan Y, Xia X, Wu Q, Chen Y, Lai Z, Yu C^*, Li W^*. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways. Hepatology. 2012;55:1820-1829.
17.Chen T, Chen Q, Xu Y, Zhou Q, Zhu J, Zhang H, Wu Q, Yu C^*. Steroid receptor coactivator 3 is required for CAR-regulated hepatocyte proliferation and drug metabolism. J Hepatol. 2012;56:210-217.